Table 1.
Demographic and clinical characteristics of patients included in this study at recruitment.
| RRMS | |
|---|---|
| n | 98 |
| Sex (% females) | 70.4 |
| Age (y.o., mean ± SD) | 40.2 ± 7.7 |
| Disease duration (m, median (P25–P75)) | 118.0 (63.3–178.0) |
| Treatment (%): | |
|
First line (beta interferon, glatiramer acetate) |
43.9 |
|
Second line (natalizumab) |
56.1 |
| Treatment duration (m, median (P25–P75)): | |
| First line | 45.0 (24.0–62.0) |
| Second line | 12.0 (2.0–27.0) |
| EDSS (median (P25–P75)) | 2.0 (1.0–3.0) |
| MSSS (median (P25–P75)) | 2.3 (0.8–4.2) |
| Annualized relapse rate (median (P25–P75)) | 0.6 (0.4–0.9) |
y.o.: years old; m: months; P: percentile; SD: standard deviation.